Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Prelude Therapeutics Inc
(NQ:
PRLD
)
4.030
+0.160 (+4.13%)
Streaming Delayed Price
Updated: 12:04 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
72,320
Open
3.990
Bid (Size)
4.000 (1)
Ask (Size)
4.040 (1)
Prev. Close
3.870
Today's Range
3.990 - 4.090
52wk Range
1.660 - 6.890
Shares Outstanding
54,808,715
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
April 09, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
March 05, 2024
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-0.99%
-0.99%
1 Month
-12.58%
-12.58%
3 Month
+30.84%
+30.84%
6 Month
+94.68%
+94.68%
1 Year
-31.35%
-31.35%
More News
Read More
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
February 29, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know
December 19, 2023
Via
Benzinga
The Latest Analyst Ratings for Prelude Therapeutics
October 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 16, 2024
Via
Benzinga
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
February 15, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
December 16, 2023
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Prelude Therapeutics Announces $25 Million Private Placement
December 11, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
November 01, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
From
Prelude Therapeutics, Inc.; AbCellera
Via
GlobeNewswire
Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday
October 19, 2023
Via
Benzinga
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
October 14, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
August 29, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
September 15, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
August 23, 2023
Via
Benzinga
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 03, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
July 31, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
July 27, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
July 28, 2023
Via
Benzinga
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
May 31, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 25, 2023
Via
Benzinga
Prelude Therapeutics Announces Pricing of Public Offering
May 18, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics Announces Launch of Proposed Public Offering
May 17, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.